Special Issue

Technologies for Influenza Vaccines that Provide Increased Speed, Efficacy and Ease of Administration

Message from the Guest Editors

This Special Issue seeks original contributions on technologies that support the development and licensure of new influenza vaccines that outperform currently licensed vaccines in efficacy, speed, flexibility, and ease of administration. Manuscripts that describe new vaccines that rely on flexible “platform technologies” (e.g., nucleic acid, recombinant proteins, and viral vectors) that shorten the time to develop a pandemic vaccine (from sequence to large-scale manufacture) are of particular interest, especially if they provide increased efficacy and ease of administration relative to current vaccines. Special consideration will be given to manuscripts on technologies to immunize naive populations with a single-dose regimen. Manuscripts that report original research findings on technologies that have demonstrated preclinical efficacy will be prioritized. This Issue will bring together innovative vaccine technologies for different respiratory viruses that could be integrated and leveraged to develop disruptive vaccines for influenza and other respiratory pathogens with pandemic potential.

Guest Editors

Dr. Ruben Donis

United States Department of Health and Human Services, Washington, DC 20201, USA

Dr. Leah Watson

United States Department, Health and Human Services, Washington, DC 20201, USA

Deadline for manuscript submissions

closed (30 November 2022)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/65617

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI